ISRCTN91792333已完成未知

Perioperative intravitreal triamcinolone in phacoemulsification for concurrent clinically significant diabetic macular oedema

Record Provided by the NHSTCT Register - 2007 Update - Department of Health0 个研究点目标入组 56 人开始时间: 2007年9月28日最近更新: 2018年2月26日

试验速览

暂无简介。

•1. Patients with Diabetic Mellitus, Type 1 or 2 Eligible
•2. Patients with cataract sufficient in an eye to cause visual symptoms
•3. Patients who have persistent CSME despite previous later treatment
•4. Patients who have moderate or severs NPDR and treated PDR as defined by a clinical modification of the Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy scale
•5. OCT measurements of <300 micron at central subfold of fats macula map

•1. Patients with no CSME
•2. High risk proliferative retinopathy as defined by the DRS 17
•3. Diabetes associated with specific genetic conditions, induced by drugs, chemicals or endocrinopathies
•4. Coexistent ocular disease
•5. Coexistent disease likely to affect retinopathy progression, for example severe carotid occlusive disease
•6. Patients with coexistent disease likely to respond poorly to side effects of intravitreal triamcinalone, including glaucoma, OHT, steroid responders
•7. Prior intraocular surgery to either eye
•8. Complicated cataract surgery

发起方

Record Provided by the NHSTCT Register - 2007 Update - Department of Health